Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥65 years with immune thrombocytopenia

Marc Michel(Université Paris-Est Créteil), Xuena Wang(Tianjin University of Traditional Chinese Medicine), Yoshiaki Tomiyama(Nobuhara Hospital), Louis M. Aledort(Icahn School of Medicine at Mount Sinai), Jeffrey S. Wasser(Community Cancer Center), Bertrand Godeau(Université Paris-Est Créteil), Mehdi Khellaf(Université Paris-Est Créteil), Nichola Cooper(Imperial College London)
Annals of Hematology
September 4, 2015
10.1007/s00277-015-2485-x
Cited by 30

Related Papers

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis.
|PubMed|2001|803
Definitions in Hemophilia
|Thrombosis and Haemostasis|2001|772
A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs
|Journal of Internal Medicine|1994|613
A More Uniform Measurement of Factor VIII Inhibitors
|Thrombosis and Haemostasis|1975|587